KELOWNA, BC, Oct. 7, 2021 /CNW/ - The Valens Company
Inc. (TSX: VLNS) (OTCQX: VLNCF)
(the "Company," "The Valens Company" or
"Valens"), a leading manufacturer of cannabis products,
is pleased to announce it will issue its third quarter 2021
financial results, for the period ended August 31, 2021, on Wednesday, October 13, 2021, after markets
close.
CONFERENCE CALL DETAILS
The Company will host a conference call the following day,
Thursday, October 14, 2021, at
11:00 am Eastern Time / 8:00 am Pacific Time to discuss the financial
results and business outlook.
Participant Dial-In Numbers:
Toll-Free: 1-877-407-0792
Toll / International: 1-201-689-8263
*Participants should request The Valens Company Earnings Call or
provide confirmation code 13723378.
The call will be available via webcast on the Valens investor
page of the Company website at
https://thevalenscompany.com/investors/ or at this link.
Please visit the website at least 15 minutes prior to the call to
register, download, and install any necessary audio software. A
replay of the call will be available on the Valens investor page
approximately two hours after the conference call has ended.
Tyler Robson, Chief Executive
Officer, Sunil Gandhi, Chief
Financial Officer, Jeff Fallows,
President, and Everett Knight,
Executive Vice President of Corporate Development and Capital
Markets, will be conducting a question-and-answer session following
the prepared remarks.
About The Valens Company
The Valens Company is a global leader in the end-to-end
development and manufacturing of innovative, cannabinoid based
products. The Valens Company is focused on being the partner of
choice for leading Canadian and international cannabis brands by
providing best-in-class, proprietary services including CO2,
ethanol, hydrocarbon, solvent-less and terpene extraction,
analytical testing, formulation and product development and custom
manufacturing. Valens is the largest third-party extraction company
in Canada with an annual capacity
of 425,000 kg of dried cannabis and hemp biomass at our
purpose-built facility in Kelowna,
British Columbia which is in the process of becoming
European Union (EU) Good Manufacturing Practices (GMP) compliant.
The Valens Company currently offers a wide range of product
formats, including tinctures, two-piece caps, soft gels, oral
sprays and vape pens as well as beverages, concentrates, topicals,
edibles, injectables, natural health products and has a strong
pipeline of next-generation products in development for future
release. Finally, The Valens Company's wholly-owned subsidiary
Valens Labs is a Health Canada
licensed ISO 17025 accredited cannabis testing lab providing
sector-leading analytical services and has partnered with Thermo
Fisher Scientific to develop a Centre of Excellence in Plant-Based
Science. For more information, please visit
https://thevalenscompany.com. The Valens Company's investor deck
can be found specifically
at https://thevalenscompany.com/investors/.
For further information, please contact:
Jeff Fallows
President
The Valens Company
Investor Relations
ir@thevalenscompany.com
1 647 956 8254
KCSA Strategic Communications
Phil Carlson / Rory Rumore
VLNS@kcsa.com
1 212.896.1233 / 1 347.237.9998
Media
KCSA Strategic Communications
Anne Donohoe
adonohoe@kcsa.com
1 212.896.1265
Notice regarding Forward Looking Statements
All information included in this press release, including any
information as to the future financial or operating performance and
other statements of The Valens Company that express management's
expectations or estimates of future performance, other than
statements of historical fact, constitute forward-looking
information or forward-looking statements within the meaning of
applicable securities laws and are based on expectations, estimates
and projections as of the date hereof. Forward-looking statements
are included for the purpose of providing information about
management's current expectations and plans relating to the future.
Wherever possible, words such as "plans", "expects", "scheduled",
"trends", "forecasts", "future", "indications", "potential",
"estimates", "predicts", "anticipate", "to establish", "believe",
"intend", "ability to", or statements that certain actions, events
or results "may", "should", "could", "would", "might", "will", or
are "likely" to be taken, occur or be achieved, or the negative of
these words or other variations thereof, have been used to identify
such forward-looking information. Specific forward-looking
statements include, without limitation, all disclosure regarding
future results of operations, future outcomes of transactions,
economic conditions, and anticipated courses of action. Investors
and other parties are advised that there is not necessarily any
correlation between the number of SKUs manufactured and shipped and
revenue and profit, and undue reliance should not be placed on such
information.
The risks and uncertainties that may affect forward-looking
statements include, among others, Canadian regulatory risk,
Australian regulatory risk, U.S. regulatory risk, U.S. border
crossing and travel bans, the uncertainties, effects of and
responses to the COVID-19 pandemic, reliance on licenses, expansion
of facilities, competition, dependence on supply of cannabis and
reliance on other key inputs, dependence on senior management and
key personnel, general business risk and liability, regulation of
the cannabis industry, change in laws, regulations and guidelines,
compliance with laws, limited operating history, vulnerability to
rising energy costs, unfavourable publicity or consumer perception,
product liability, risks related to intellectual property, product
recalls, difficulties with forecasts, management of growth and
litigation, many of which are beyond the control of The Valens
Company. For a more comprehensive discussion of the risks faced by
The Valens Company, and which may cause the actual financial
results, performance or achievements of The Valens Company to be
materially different from estimated future results, performance or
achievements expressed or implied by forward-looking information or
forward-looking statements, please refer to The Valens Company's
latest Annual Information Form filed with Canadian securities
regulatory authorities at www.sedar.com or on The Valens Company's
website at www.thevalenscompany.com. The risks described in such
Annual Information Form are hereby incorporated by reference
herein. Although the forward-looking statements contained herein
reflect management's current beliefs and reasonable assumptions
based upon information available to management as of the date
hereof, The Valens Company cannot be certain that actual results
will be consistent with such forward-looking information. The
Valens Company cautions you not to place undue reliance upon any
such forward-looking statements. The Valens Company disclaims any
intention or obligation to update or revise any forward-looking
statements whether as a result of new information, future events or
otherwise, except as required by applicable law. Nothing herein
should be construed as either an offer to sell or a solicitation to
buy or sell securities of The Valens Company.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/the-valens-company-to-hold-conference-call-to-discuss-financial-results-for-the-third-quarter-of-2021-301394713.html
SOURCE The Valens Company Inc.